Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system

Thrombosis Research

Volumn 134, Issue 6, 2014, Pages 1365-1367

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; FR 171113; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 INHIBITOR; RECEPTOR BLOCKING AGENT; SUPEROXIDE; THROMBIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL ADHESION ASSAY; CELL DAMAGE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COCULTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; GENE EXPRESSION REGULATION; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; MESANGIUM CELL; OXIDATIVE STRESS; RENAL PROTECTION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; HUMANS; MESANGIAL CELLS; PYRAZOLES; PYRIDONES; RECEPTOR, PAR-1; THROMBIN;

EID: 84916215005     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.09.028     Document Type: Letter

References (14)

1. H. Reinecke, M. Nabauer, A. Gerth, T. Limbourg, A. Treszl, and C. Engelbertz Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease Kidney Int 2014 10.1038/ki.2014.195
2. Y. Ahmad, and G.Y. Lip Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation Contrib Nephrol 179 2013 81 91
3. D. Tsiachris, C. Tsioufis, P. Mazzone, N. Katsiki, and C. Stefanadis Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad Curr Vasc Pharmacol 2014 10.2174/1570161112666140519154615
4. S. Apostolakis, Y. Guo, D.A. Lane, H. Buller, and G.Y. Lip Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial Eur Heart J 34 2013 3572 3579
5. V. Roldán, F. Marín, S. Manzano-Fernandez, H. Fernández, P. Gallego, and M. Valdés Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109 2013 956 960
6. R.G. Hart, J.W. Eikelboom, K.S. Brimble, M.S. McMurtry, and A.J. Ingram Stroke prevention in atrial fibrillation patients with chronic kidney disease Can J Cardiol 29 2013 S71 S78
7. S.H. Hohnloser, Z. Hijazi, L. Thomas, J.H. Alexander, J. Amerena, and M. Hanna Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
8. Y. Ishibashi, T. Matsui, S. Ueda, K. Fukami, and S. Yamagishi Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression Cardiovasc Diabetol 13 2014 60
9. A.E. Stinghen, S.M. Gonçalves, E.G. Martines, L.S. Nakao, M.C. Riella, and C.A. Aita Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease Nephron Clin Pract 111 2009 c117 c126
10. F. Chiarelli, F. Cipollone, A. Mohn, M. Marini, A. Iezzi, and M. Fazia Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes Diabetes Care 25 2002 1829 1834
11. S.D. Ye, M. Zheng, L.L. Zhao, Y. Qian, X.M. Yao, and A. Ren Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy Eur J Clin Invest 39 2009 980 985
12. A. Upadhyay, M.G. Larson, C.Y. Guo, R.S. Vasan, I. Lipinska, and C.J. O'Donnell Inflammation, kidney function and albuminuria in the Framingham Offspring cohort Nephrol Dial Transplant 26 2011 920 926
13. J.A. Cairns Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices Can J Cardiol 29 2013 1165 1172
14. B.K. Poulsen, E.L. Grove, and S.E. Husted New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function Drugs 72 2012 1739 1753